Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Short-term Investments (2020 - 2025)

Protalix BioTherapeutics (PLX) has 6 years of Short-term Investments data on record, last reported at $15.7 million in Q3 2025.

  • For Q3 2025, Short-term Investments changed N/A year-over-year to $15.7 million; the TTM value through Sep 2025 reached $15.7 million, changed N/A, while the annual FY2024 figure was $15.1 million, 27.98% down from the prior year.
  • Short-term Investments reached $15.7 million in Q3 2025 per PLX's latest filing, up from $15.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $50.6 million in Q1 2021 and bottomed at $5.1 million in Q4 2022.
  • Average Short-term Investments over 5 years is $21.7 million, with a median of $16.1 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: crashed 73.46% in 2022, then soared 312.82% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $38.0 million in 2021, then crashed by 86.67% to $5.1 million in 2022, then soared by 312.82% to $20.9 million in 2023, then decreased by 27.98% to $15.1 million in 2024, then grew by 4.33% to $15.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $15.7 million in Q3 2025, $15.5 million in Q2 2025, and $15.3 million in Q1 2025.